The Malta Conferences address the shared desire to improve quality of life and political stability in the Middle East through scientific collaboration
HAIFA, Israel, Oct. 01, 2020 On Wednesday, September 30, 2020, Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading Israeli regenerative medicine company developing a platform of novel biological products, and the Abu Dhabi Stem Cells Center (ADSCC) unveiled their first joint projects in a presentation at the Malta Conferences Foundation, a global conference supported by the kENUP Foundation, a global promoter of research-based innovation with public and societal benefit.
Pluristem and ADSCC presented the new projects, part of the recently signed Memorandum of Understanding (MOU) aimed at harnessing the power of regenerative medicine.
The first joint project brings together the expertise and knowledge of Pluristem and ADSCC to advance a potential COVID-19 treatment. The project will involve the first-time administration of Pluristems PLX cells via a nebulizer, a drug delivery device that helps a patient inhale a medication through a mask or mouthpiece, to COVID-19 patients. The collaboration will allow ADSCC to expand its stem cell therapy options using Pluristems novel PLX cells, while enabling Pluristem to leverage ADSCCs nebulizer administration experience to develop a new treatment delivery model for PLX cells. ADSCC has reported effectively using nebulizers to treat patients suffering from COVID-19 infection with stem cells sourced from the patients own blood.
Further discussions for additional projects are underway, including for the potential collaboration in chronic Graft Versus Host Disease (cGvHD), a life-threatening immune response of the donors stem cells against the host (patient).
The parties presented the joint projects to a distinguished audience at the Malta Conferences Foundation, including Nobel Laureates, scientists, and diplomats. The foundations mission is to address the shared desire to improve the quality of life and political stability in the Middle East by identifying unique opportunities for collaboration to meet the scientific and technological challenges of the region.
I am delighted by the opportunity to convene this important meeting. The Malta Conferences are the only platform in the world where scientists from 15 Middle East countries, Morocco and Pakistan can get together under the same roof with several Nobel Laureates. They develop collaborations and friendship which overcome the chasms of distrust and intolerance. said Prof. Zafra Lerman, President of Malta Conferences Foundation.
Embarking on this journey with Pluristem, to overcome one of this generations most complex medical challenges, marks an exciting new chapter full of possibilities when it comes to knowledge sharing and medical innovation. Our partnership speaks volumes about the power of collaboration between partners across previously divided borders.While we simply do not yet know the long-term impact, the novel coronavirus will have on recovered patients, by working together we believe that we are able to leverage the best medical technologies and minds in the region to develop solutions to prevent and treat the lingering symptoms and long-term complications that are emerging, saidDr. Yendry Ventura, General Manager of ADSCC.
We were very honored to unveil our first joint projects with the ADSCC at the Malta Conferences Foundation. We see our partnership as a movement between Israel and the UAE, which we hope will lay the foundation for future collaborations that will help potentially bring change to our region and the entire world. As we work together to develop regenerative medicine for key unmet medical needs of benefit to patients around the world, we are excited for the future and its possibilities, stated Pluristem CEO and President Yaky Yanay.
Two world-class players in the field of cell therapy join forces and cooperate on the fight of COVID-19. May this courageous cooperation serve as an example to the world, says kENUP Foundations Executive Chairman, Holm Keller.
About Malta Conferences The foundations mission is to address the shared desire to improve quality of life and political stability in the Middle East by identifying unique opportunities for collaboration to meet the scientific and technological challenges of the region. The Malta Conferences deal with issues of science education, air and water quality, and alternative energy sources, among other topics of mutual interest. Global leaders have recognized that science diplomacy is an extremely important mechanism for working toward stability in the Middle East, and this is what the Malta Conferences have done for the past 17 years.
About Abu Dhabi Stem Cells Center Abu Dhabi Stem Cells Center (ADSCC) is an Abu Dhabi-based specialist healthcare center focused on cell therapy and regenerative medicine, as well as delivering cutting-edge research on stem cells in the region. The Center was founded in March 2019 to meet growing domestic and regional demand for highly specialized medical services and treatments. Equipped with the latest technologies, medical devices which are unique to the region, and a team of internationally recognized doctors working hand in hand with researchers, ADSCC is the first of its kind in the UAE. ADSCC specialties include immunology, hematology, clinical stem cell therapy, molecular biology, immunotherapy, orthopedics, and urology amongst others.
About kENUP Foundation kENUP is a global partnership in innovation, promoting research-based innovation for Europe with public and societal benefit. It is a not-for-profit organization established as a foundation in the Republic of Malta by Public Deed on November 6, 2014. kENUPs activities are published in the European Transparency Register.The Foundation supports European corporations active in industries with substantive underlying market failures bypreparing corporate innovation programs for an investment by theEuropean Investment Bank(EIB), or by other publicinvestmentbanks in the EU, often in close collaboration with private or venture investors.
About Pluristem Therapeutics Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Companys proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.
Safe Harbor Statement This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses its first project with ADSCC and that such collaboration will allow ADSCC to expand its stem cell therapy options using its novel PLX cells, while enabling it to leverage ADSCCs nebulizer administration experience to develop a new treatment delivery model for PLX cells, potential future projects with ADSCC, including the potential collaboration in chronic GvHD, the belief that it and ADSCC are able to leverage the best medical technologies and minds in the region to develop solutions to prevent and treat the lingering symptoms and long-term complications that are emerging and that it sees its partnership with ADSCC as a movement between Israel and the UAE, which it hopes will lay the foundation for future collaborations that will help potentially bring change to its region and the entire world. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristems products may not be approved by regulatory agencies, Pluristems technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristems process; Pluristems products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristems patents may not be sufficient; Pluristems products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristems reports filed from time to time with the Securities and Exchange Commission.
Contact: Dana Rubin Director of Investor Relations 972-74-7107194 [emailprotected]
See the original post here:
- Stem Cell Banking Market Size To Surpass USD 19.29 Billion By 2030, Exhibiting A CAGR Of 13.69% As Revealed... - WhaTech - March 18th, 2024
- Stem Cell Banking Market Size, Share, Competitive Landscape and Trend Analysis and Industry Forecast, - EIN News - January 18th, 2024
- Stem Cell Banking Market Predicted to Witness Steady Growth ... - Digital Journal - September 8th, 2023
- Stem Cell Banking Market Expected To Reach $16.55 Billion by 2030 | CAGR 15.6% - EIN News - September 7th, 2023
- Stem Cell Banking Market Trends: Industry Analysis and Growth Projections Through 2030 - Benzinga - September 3rd, 2023
- Stem Cell Banking Market Report: Analysis of Effective Business ... - Digital Journal - August 30th, 2023
- Stem Cell Banking Market Expected To Reach $16.55 Billion by 2030 | CAGR of 15.6% - openPR - July 19th, 2023
- Stem Cell Banking Market expected to reach USD 16,474.30 million by 2029 - openPR - July 8th, 2023
- Global Stem Cell Banking Market is expected to reach a market size of ~US$ 15 billion by 2028: Ken Research - openPR - June 8th, 2023
- Stem Cell Banking Market: CAGR of 8.2% and Market Valuation ... - KaleidoScot - June 8th, 2023
- Cord Stem Cell Banking Market Size to Surpass USD 45.64 Billion with CAGR of 22% by 2030 - openPR - June 4th, 2023
- Forecasting the Future of the Stem Cell Banking Market : Trends and Insights | CCBC, Crioestaminal, Esperite, - openPR - April 29th, 2023
- Stem Cell Banking Market Expected To Reach $16.55 Billion by 2030 | Current Trends and Industry Analysis - EIN News - April 27th, 2023
- Stem Cell Banking Offers Health And Investment Opportunity - ValueWalk - April 21st, 2023
- Stem Cell Banking Offers Health and Investment Opportunity ... - SavingAdvice.com - April 19th, 2023
- Cord Stem Cell Banking Market to Influence the Value of USD 45.64 Billion by 2030 - openPR - April 12th, 2023
- Stem Cell Banking Market Size Expected to Reach USD 16,474.30 Million by 2029 with 16.1% CAGR - openPR - March 29th, 2023
- What is Stem Cell Banking? | Cells4Life - March 19th, 2023
- What is Stem Cell Banking? | Cells4Life - March 19th, 2023
- Stem Cell Banking Market Top-Players And Qualitative Future ... - Digital Journal - February 13th, 2023
- Global Stem Cell Banking Market Overview, Regional Analysis, Market Share and Competitive Analysis - openPR - February 4th, 2023
- What is Stem Cell Banking? | Stem Cell Preservation in India | Stem ... - January 7th, 2023
- Stem Cell & Cord Blood Banking Dubai, UAE - CellSave Arabia - January 5th, 2023
- Donate Stem Cells | Bone Marrow Donation - American Cancer Society - January 5th, 2023
- Private stem cell banking & genetic screening | Future Health Biobank - December 24th, 2022
- Stem Cell Banking Outsourcing Market is anticipated to expand at a ... - Digital Journal - December 20th, 2022
- Stem Cell Banking market size is estimated to be worth USD 1789 million in 2021 and is forecast to a readjuste - openPR - December 15th, 2022
- Stem Cell Banking Market To Reach USD 2927.2 Million By 2028 With A CAGR of 7.2% | Valuates Reports - Yahoo Finance - December 11th, 2022
- Stem Cell Banking Market registering a CAGR of 16.1% by forecast 2029 - openPR - December 1st, 2022
- Stem Cell Banking Industry 2022 - 2028 Market Analysis by Regions, Types and Application - openPR - November 6th, 2022
- Stem Cell Banking & Therapy In India | ReeLabs - October 25th, 2022
- Worldwide Stem Cell Banking Industry to 2027 - Rising Number of Fatal ... - October 25th, 2022
- Global Stem Cell Umbilical Cord Blood (UCB) Market Report 2022-2026: Increased Federal Investment in Stem Cell Therapy, and the Advent of Cord Blood... - October 25th, 2022
- Placental Stem Cell Therapy Market - Know the Latest Profit Sources of the Industry - openPR - October 18th, 2022
- Outlook on the Cord Blood Banking Services Global Market to 2027 - by Component, Storage Services, Application and Region - GlobeNewswire - October 13th, 2022
- Cell & Tissue Preservation Market Size will Observe Lucrative Surge by the End 2031 - openPR - October 12th, 2022
- News from the world of Education: October 12, 2022 - The Hindu - October 12th, 2022
- Stemcord | Home - October 9th, 2022
- Global Cord Blood Banking Market - Competition Forecast and Opportunities, 2027 - Yahoo Finance - October 9th, 2022
- Cell Banking Outsourcing Market Analysis By Trends, Size, Share, Company Overview, Growth And Forecast By 2031 The Colby Echo News - The Colby Echo... - October 4th, 2022
- Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands - Business Wire - September 29th, 2022
- Biobanking Market Size to Surge at the CAGR of 5.9% from 2022-2031 - Digital Journal - September 19th, 2022
- Stem Cell Banking Solutions | Hope Biosciences - September 19th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - Benzinga - September 17th, 2022
- Stem Cell Banking Market to Witness Massive Growth by 2029 | CCBC, CBR - Fighting Hawks Magazine - Fighting Hawks Magazine - September 15th, 2022
- Stem Cell Banking Market Analysis, 2031: Advancements in the field of Regenerative Medicine - BioSpace - September 15th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - GlobeNewswire - September 15th, 2022
- Cord Blood Banking Services Market Size Estimated to Reach $3.6 Billion By 2027 at a CAGR of 11.8% During Forecast Period 2022-2027. - Digital Journal - August 30th, 2022
- Applied StemCell expands manufacturing facility to support cell and gene therapies - BioPharma-Reporter.com - August 30th, 2022
- What is Cord Blood Banking? - Benzinga - August 30th, 2022
- Vita 34 records moderate upward trend in the second quarter - PharmiWeb.com - August 30th, 2022
- dental stem cell banking - National Dental Pulp Laboratory - August 29th, 2022
- Global Cell Banking Outsourcing Market to Grow at a CAGR of ~18% during 2022-2031; Market to Expand Owing to the Development of Advanced Cell... - August 24th, 2022
- Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells - Nature.com - August 12th, 2022
- Stem cell therapy to be used in treatment of long COVID by Panacell Biotech - Labiotech.eu - August 10th, 2022
- Building a healthtech industry in Europe to serve patients - Labiotech.eu - August 9th, 2022
- Cell & Gene Therapy Manufacturing Services Market Research Report : With Healthy CAGR 7.8% : Will Reach USD 56.7 Billion by 2028 - Digital Journal - August 6th, 2022
- Oldest patient yet cured of HIV after stem cell transplant researchers - Global Banking And Finance Review - July 28th, 2022
- Stem Cell Banking Market Size to Accelerate at a Rapid CAGR of 16.1% from 2022 to 2029 - Digital Journal - July 25th, 2022
- Global Stem Cell Banking Outsourcing Market 2022 Trend Analysis, Growth Status, Revenue Expectation to 2028 This Is Ardee - This Is Ardee - July 19th, 2022
- Xilis Announces Series A Extension, Bringing Total Round to Over US$89 Million - Business Wire - July 14th, 2022
- Stem Cell Banking Market Detailed In New Research Report 2022 | Allergan, Plc., Galderma S.A., Integra LifeSciences Corporation, Merz Pharma GmbH... - July 12th, 2022
- Global Cord Blood Corporation Obtained Injunction Order Against Blue Ocean in respect of Purported EGM - Yahoo Finance - July 7th, 2022
- Cord Stem Cell Banking Market Size, Global Industry, Share, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis by DBMR... - July 7th, 2022
- Allogenic Stem Cell Therapy Market Research by Size, Share, Trends, Business Opportunities and Top Manufacture and Forecast by 2027 Designer Women -... - July 7th, 2022
- expert reaction to study that uses freeze-dried somatic cells to produce cloned mice - Science Media Centre - July 5th, 2022
- South Korea Stem Cell Banking Market Report 2022 - ResearchAndMarkets.com - Business Wire - July 4th, 2022
- Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., ... - The Bakersfield Californian - June 30th, 2022
- NorthX jumps into cell therapies with help from Alder - Bioprocess Insider - BioProcess Insider - June 28th, 2022
- NorthX Biologics expands to Cell Therapy: Partnership with Alder Therapeutics and new manufacturing site on Karolinska campus - PharmiWeb.com - June 26th, 2022
- Cord Stem Cell Banking Market Size, Share, Application, Trends, Growth, Opportunities and Worldwide Forecast Designer Women - Designer Women - June 24th, 2022
- Indian Optical Brightening Agents Market To Be Driven By Rising Manufacturing Operations In The Forecast Period Of 2022-2027 Designer Women -... - June 22nd, 2022
- NorthX Biologics expands to Cell Therapy: Partnership with Alder Therapeutics and new manufacturing site on Karolinska campus - Yahoo Finance UK - June 22nd, 2022
- Stem Cell Banking Market Global Outlook on Key Growth Trends, Factors and Forecast 2028: Cord Blood Registry (CBR) Systems, Inc.,Cryo-Cell... - June 22nd, 2022
- Pricing & Payment Plans | AlphaCord - Newborn Stem Cell Banking - June 20th, 2022
- Global Cholera Vaccine Market Garnered a Revenue of Approximately USD 68 Million in 2021 and Further Touch a CAGR of ~7% During 2022-2030; Market to... - June 20th, 2022
- Global Potash Fertilisers Market To Be Driven By Changing Food Habits Among Customers In The Forecast Period Of 2022-2027 Designer Women - Designer... - June 18th, 2022
- Stem Cell Banking Outsourcing Market 2022 with a CAGR of %, prime firms report covers, business Outlook, In-depth Analysis Business Opportunities and... - June 18th, 2022
- Global Stem Cell Banking Market To Be Driven At A CAGR Of 13.5% In The Forecast Period Of 2021-2026 Designer Women - Designer Women - June 15th, 2022
- The age reversal tech that billionaires are banking on - Freethink - June 15th, 2022
Recent Comments